Multiple peer-reviewed publications have consistently demonstrated a set of blood-based protein biomarkers associated with idiopathic pulmonary fibrosis (IPF) disease progression. A set of...
The outbreak of the SARS-CoV-2 virus caused a sudden shift in focus for the pharmaceutical industry. After the genetic sequence of the virus was released in early 2020, manufacturers across the globe...
This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola. At Q2 Solutions, we support infectious disease clinical trials with a...
Data collected from clinical trials helps advance the field of medicine, and both the usage and sharing of clinical trial data are important in drug development. In order to improve the efficiency...
Download this white paper to learn more about the challenges and the importance of neutralizing antibodies assays and immunogenicity strategy in drug development to assess and mitigate risk....